UAE Hypersomnia Therapeutics Market Analysis

UAE Hypersomnia Therapeutics Market Executive Summary

The UAE Hypersomnia Therapeutics Market is at around $41.83 Mn in 2023 and is projected to reach $69.39 Mn in 2030, exhibiting a CAGR of 7.5% during the forecast period.

Hypersomnia is a group of neurological disorders characterized by excessive daytime sleepiness, despite getting enough sleep at night. This can significantly impair daily functioning and reduce quality of life. While the exact causes are still being researched, hypersomnia can be linked to underlying medical conditions, neurological disorders, or disruptions in sleep regulation mechanisms. People with hypersomnia often experience symptoms such as not feeling refreshed upon waking, feeling groggy and slow for extended periods after waking, and an excessive need for sleep despite sleeping for long periods. Chronic headaches, loss of appetite, excessive sweating, and depression have also been reported. Treatment for hypersomnia focuses on managing daytime sleepiness. This can involve adopting healthy lifestyle practices like eating well and exercising regularly. Medications like stimulants can also be prescribed to promote wakefulness. In some cases, cognitive behavioral therapy for insomnia (CBT-I) can help address underlying sleep habits that contribute to hypersomnia.

The prevalence of hypersomnia in UAE is estimated to be around 0.5 to 5% of the general population. The market therefore is driven by significant factors like the increasing awareness about hypersomnia disorders, rising prevalence, and advances in sleep disorder research. However, high costs of treatment, limited accessibility to specialized healthcare services, and strict regulatory approval restrict growth of the market

Since there is no cure for hypersomnia, treatment currently focuses on managing symptoms, particularly excessive daytime sleepiness. The leading pharmaceutical companies include Teva Pharmaceuticals for the treatment of hypersomnia disorders in UAE. Sahara Pharmaceuticals, BIOPROJET, and Neopharma are also significant contributors to the hypersomnia therapeutics landscape, with continuous research and development activities.

Market Dynamics

Market Growth Drivers

Increasing Awareness about Hypersomnia Disorders: Increased public awareness campaigns and healthcare professional education are leading to more accurate diagnoses, raising the potential patient pool for these medications. Dubai Hospital has held a campaign to help improve public knowledge about the signs, symptoms, complications, diagnosis, and treatment options for sleep problems.

Expanding Geriatric Population: Hypersomnia may be more common among elderly individuals, as a result of alterations in sleep patterns and existing health issues. Given that the geriatric demographic makes up 2% of the population, the incidence of hypersomnia disorders is projected to increase, leading to a greater need for specialized treatment approaches designed specifically for older adults.

Advances in Sleep Disorder Research: Advances in sleep disorder research and the development of new treatments, such as multiple sleep latency tests (MSLT), are enhancing the accuracy of hypersomnia diagnosis, leading to increased demand for treatment.

Market Restraints

High costs of treatment: The costs associated with the development and commercialization of hypersomnia drugs are significant. This financial burden restricts access to these medications, particularly in a healthcare system where coverage may be limited for certain treatments, making it difficult for patients to afford long-term therapy

Strict Regulatory Approval Process: The regulatory framework for pharmaceuticals in the UAE is stringent, requiring extensive testing and compliance with guidelines set by authorities such as the Ministry of Health and Prevention (MOHAP). This leads to delays in the approval and availability of new hypersomnia treatments, limiting market access to innovative therapies

Limited Accessibility to Specialized Healthcare Services: Sleep disorder clinics, neurologists, and sleep medicine specialists are difficult to access in some regions, including rural ones. Untimely diagnosis, inappropriate treatment, and insufficient ongoing care for individuals with hypersomnia cause underdiagnosis and undertreatment of the condition.

Regulatory Landscape and Reimbursement Scenario

The regulatory landscape for pharmaceuticals in UAE is governed primarily by the UAE Ministry of Health and Prevention (MOHAP). The regulatory framework is designed to ensure the safety, efficacy, and quality of pharmaceutical products available in the market. Before a pharmaceutical product can be marketed and sold in the UAE, it must undergo a rigorous registration process with MOHAP. It also regulates pharmaceutical prices in the UAE.

To seek drug approval, an electronic application is submitted for the drug's registration. MOHAP's technical committees then meticulously review the application and all submitted documents. After the technical review, the committees make recommendations that are forwarded to a ministerial committee for final approval.

In Abu Dhabi, Thiqa is the mandatory health insurance plan for their residents. It offers comprehensive coverage for in-patient and out-patient care at government healthcare facilities. For treatment outside the emirate, Thiqa reimburses 50% of the cost. Dubai's mandatory health insurance plan provides coverage for essential healthcare services at designated DHA facilities. There are different coverage tiers available, allowing residents to choose a plan that meets their needs and budget

Competitive Landscape

Key Players

Here are some of the major key players in the UAE Hypersomnia Therapeutics Market:

• Teva Pharmaceuticals
• Jazz Pharmaceuticals
• Johnson & Johnson
• Al Hayat Pharmaceuticals
• Sahara Pharmaceuticals
• BIOPROJET
• Merck
• Neopharma
• NewBridge Pharmaceuticals Ltd.
• Roche
• GlaxoSmithKline
• Theranexus